You just read:

Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

News provided by

Eli Lilly and Company

Jun 11, 2019, 03:00 ET